Cargando…
Bioavailability, safety, and pharmacodynamics of delayed-release dexlansoprazole administered as two 30 mg orally disintegrating tablets or one 60 mg capsule
BACKGROUND: Dual delayed-release dexlansoprazole is approved for use in adults as a 30 mg orally disintegrating tablet (ODT) or as 30 mg and 60 mg capsules. The pharmacokinetics, pharmacodynamics, and safety profile of two dexlansoprazole 30 mg ODTs were compared with one dexlansoprazole 60 mg capsu...
Autores principales: | Kukulka, Michael, Nudurupati, Sai, Perez, Maria Claudia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5076775/ https://www.ncbi.nlm.nih.gov/pubmed/27803732 http://dx.doi.org/10.1177/1756283X16666800 |
Ejemplares similares
-
Pharmacokinetics and pharmacodynamics of an orally disintegrating tablet formulation of dexlansoprazole
por: Kukulka, Michael, et al.
Publicado: (2016) -
Bioavailability of a dexlansoprazole delayed-release orally disintegrating tablet: effects of food and mode of administration
por: Kukulka, Michael, et al.
Publicado: (2017) -
Comparator pH study to evaluate the single-dose pharmacodynamics of dual delayed-release dexlansoprazole 60 mg and delayed-release esomeprazole 40 mg
por: Kukulka, Michael, et al.
Publicado: (2011) -
Bioavailability of dexlansoprazole delayed-release capsule granules when administered via nasogastric tube or orally via syringe
por: Kukulka, Michael, et al.
Publicado: (2018) -
Pharmacokinetics and safety of dexlansoprazole MR in pediatric patients with symptomatic gastroesophageal reflux disease
por: Kukulka, Michael, et al.
Publicado: (2014)